Loading…
Processa Pharmaceuticals, Inc. is projected to decline to $1.79 by 2027, a -11% move from its current price of $2.02. PCSA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.91 | $2.02 | $2.13 | 0.00% |
| Jul 14 | $1.87 | $2.02 | $2.18 | +0.01% |
| Jul 15 | $1.84 | $2.02 | $2.22 | +0.01% |
| Jul 16 | $1.81 | $2.02 | $2.25 | +0.01% |
| Jul 17 | $1.79 | $2.02 | $2.28 | +0.01% |
| Jul 18 | $1.77 | $2.02 | $2.31 | +0.02% |
| Jul 19 | $1.75 | $2.02 | $2.33 | +0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.75 | $2.02 | $2.33 | +0.02% |
| Week 2 | $1.65 | $2.02 | $2.48 | +0.04% |
| Week 3 | $1.57 | $2.02 | $2.59 | +0.06% |
| Week 4 | $1.52 | $2.02 | $2.70 | +0.08% |
| Week 5 | $1.47 | $2.02 | $2.79 | +0.10% |
| Week 6 | $1.42 | $2.02 | $2.88 | +0.12% |
| Week 7 | $1.38 | $2.02 | $2.96 | +0.14% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company in the Healthcare sector, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. Its drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells.
Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. It also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited.
Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.
Processa Pharmaceuticals, Inc. (PCSA) is currently priced at $1.89 with a market capitalization of $5.23M and it ranks 5320 by market cap.
The stock trades in the Healthcare space and carries a current price of $1.89 with a $5.23M market cap and a rank of 5320. The near-term technical picture remains NEUTRAL, with an RSI14 of 40, a SMA50 of $2.45, and a SMA200 of $4.14. Support is noted at $1.86 and resistance at $2.92.
Over the last 30 days, the price has fluctuated between $1.32 and $2.71, and the stock exhibits high volatility with an annualized volatility of 100%.
Looking further out, the long-term forecast shows a path of evolving values across the years, with notable milestones in the mid-2020s through 2050. The 2032 outlook is bullish with an average around $2.54 and a max near $4.71, while the 2040 outlook remains bullish with an average near $3.16 and a max near $6.95, continuing into 2050 at an average around $5.82 and a max near $13.38.
A major floor 38.0% below — a decisive break under it would weaken the trend.
The nearest floor, 7.9% below — buyers have tended to step in here.
The nearest ceiling, 44.6% above — a clean break opens room to run.
A major ceiling 67.0% above — clearing it would confirm fresh momentum.
Key PCSA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PCSA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.00 | Buy | $2.03 | Sell |
| MA 10 | $1.99 | Buy | $2.02 | Buy |
| MA 20 | $2.04 | Sell | $2.09 | Sell |
| MA 50 | $2.39 | Sell | $2.32 | Sell |
| MA 100 | $2.52 | Sell | $2.75 | Sell |
| MA 200 | $4.09 | Sell | $4.92 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.46 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 66.10 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 6.93 | Buy |
| Bollinger %B (20,2) | 0.72 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.94 | Sell |
| Awesome (5,34) | -0.24 | Sell |
| Ultimate (7,14,28) | 58.44 | Neutral |
| Momentum (10) | 0.27 | Buy |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 1.98 | Buy |
| ADX (14) | 15.49 | Neutral |
| ATR (14) | 0.11 | Info |
The 30-day technical picture is neutral overall. RSI14 sits at 40, indicating neither overbought nor oversold conditions. The stock’s short-term trend sits around the $2.50 area, with the 50-day moving average at $2.45 and the 200-day moving average at $4.14, suggesting that near-term price action could face resistance near $2.92 and relative support near $1.86.
In the last 30 days, the price has traded between $1.32 and $2.71, underscoring a relatively tight range with notable upside and downside potential. The annualized volatility is high at 100%, highlighting substantial risk and potential for rapid moves in either direction.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.85 | $2.02 | $2.38 | 0% | Neutral | |
| $1.30 | $1.79 | $2.67 | -11% | Neutral | |
| $1.02 | $1.50 | $2.38 | -26% | Bearish | |
| $1.25 | $1.92 | $3.21 | -5% | Neutral | |
| $1.45 | $2.35 | $4.07 | +16% | Neutral | |
| $1.46 | $2.47 | $4.43 | +22% | Bullish | |
| $1.61 | $2.83 | $5.25 | +40% | Bullish | |
| $1.33 | $2.45 | $4.66 | +21% | Bullish | |
| $1.11 | $2.12 | $4.14 | +5% | Neutral | |
| $1.20 | $2.38 | $4.76 | +18% | Neutral | |
| $1.63 | $3.63 | $7.97 | +80% | Bullish | |
| $3.11 | $6.92 | $15.91 | +243% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.85 | $2.02 | $2.40 | +0.00% |
| August 2026 | $1.62 | $1.97 | $2.48 | -2.69% |
| September 2026 | $1.65 | $2.03 | $2.61 | +3.03% |
| October 2026 | $1.54 | $1.91 | $2.51 | -5.64% |
| November 2026 | $1.40 | $1.75 | $2.33 | -8.19% |
| December 2026 | $1.39 | $1.77 | $2.38 | +0.83% |
Click any year to see its month-by-month PCSA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect PCSA to range from $1.85 to $2.38 through 2026. The $2.02 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The PCSA price prediction for 2027 points to an average of $1.79 (low $1.30, high $2.67) — a potential decline of -11% on today's $2.02. A consolidation phase looks the most probable path here.
In 2028, PCSA is projected to trade between $1.02 and $2.38, averaging $1.50 — a potential decline of -26% from today's $2.02. That is -16% versus the projected 2027 average. A cyclical pullback looks likely — prices rarely move in a straight line.
Processa Pharmaceuticals, Inc.'s 2029 outlook centres on $1.92, within a $1.25 to $3.21 range. That is up +28% on the projected 2028 average. That marks a -5% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, PCSA could reach as high as $4.07, with a base case around $2.35 and support toward $1.45 — roughly +16% from $2.02. Price action looks broadly range-bound.
Expect PCSA to range from $1.46 to $4.43 through 2031. The $2.47 average target implies a +22% move from current prices. That is up +5% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The PCSA price prediction for 2032 points to an average of $2.83 (low $1.61, high $5.25) — a potential gain of +40% on today's $2.02. Momentum favours further upside here.
In 2033, PCSA is projected to trade between $1.33 and $4.66, averaging $2.45 — a potential gain of +21% from today's $2.02. That is -14% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Processa Pharmaceuticals, Inc.'s 2034 outlook centres on $2.12, within a $1.11 to $4.14 range. That is -13% versus the projected 2033 average. That marks a +5% change versus current levels. Price action looks broadly range-bound.
By 2035, PCSA could reach as high as $4.76, with a base case around $2.38 and support toward $1.20 — roughly +18% from $2.02. A consolidation phase looks the most probable path here.
Expect PCSA to range from $1.63 to $7.97 through 2040. The $3.63 average target implies a +80% move from current prices. That is up +52% on the projected 2035 average. Momentum favours further upside here.
The PCSA price prediction for 2050 points to an average of $6.92 (low $3.11, high $15.91) — a potential gain of +243% on today's $2.02. Buyers look set to stay in control over this stretch.
Investing $1,000 in PCSA today (≈ 495.049505 PCSA) could be worth
$3,425.24
+$2,425.24 (+243%) by 2050 · US Dollar
Based on the average projected PCSA price of $6.92 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PCSAwould be worth at today's price.
$1,000 invested in PCSA on Jul 10, 2025 (≈ 173.913043 PCSA) would be worth
$351.3
-$648.7 (-64.9%) today · 0.35× · US Dollar
Based on a PCSA entry price of $5.75 vs. today's $2.02.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.16 | $935.19 | -6.5% |
| 1 month ago | $1.98 | $1,020.2 | +2.0% |
| 3 months ago | $2.77 | $729.24 | -27.1% |
| 6 months ago | $3.14 | $643.31 | -35.7% |
| 1 year ago | $5.75 | $351.3 | -64.9% |
| All time (5.0y) ago | $3,685 | $0.55 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PCSA forecast.
Our base-case forecast reaches $4.00 around 2050.
Implied market cap at $4.00: $11.07M
The multi-year forecast shows a mix of potential outcomes with growing upside in later years. In 2030, the average price is forecast at $2.06 with an ROI of 8.9 and a neutral sentiment; the range for 2030 is $1.27 to $3.57. By 2032, the average rises to $2.54 with a bullish signal and an ROI of 34.5, within a $1.44 to $4.71 range.
The trajectory continues to 2040, where the average is forecast at $3.16 with an ROI of 67.4 and a bullish sentiment, within a $1.42 to $6.95 range. By 2050, the average is forecast at $5.82 with an ROI of 207.7 and a bullish sentiment, in a range from $2.62 to $13.38. Notably, earlier years show bearish phases (for example, 2028 with an average of $1.36 and ROI -27.9; 2027 with $1.65 and ROI -12.7), illustrating the presence of downside risk alongside longer-term upside potential.
Overall, the long-range view points to meaningful upside potential in the 2030s and 2040s, conditional on market factors and execution of the company’s clinical program. The forecast emphasizes that these are estimates rather than guarantees, and that significant volatility and risk remain inherent to the stock’s sector and development timelines.
Tap a question to reveal the answer.
The forecast for 2030 shows min $1.27, avg $2.06, max $3.57 with ROI 8.9 and sentiment NEUTRAL.
Forecasts show mixed outcomes: bearish years (e.g., 2028 min $0.93, avg $1.36, max $2.17 with ROI -27.9) and bullish years (e.g., 2050 min $2.62, avg $5.82, max $13.38 with ROI 207.7). The current price is $1.89, but outcomes are not guaranteed.
Yes, the 2030 max is $3.57, indicating a possible move above $3 in that year, though it is not guaranteed.
Current price is $1.89 and the market cap is $5.23M.
2040: avg $3.16, max $6.95, ROI 67.4, sentiment BULLISH. 2050: avg $5.82, max $13.38, ROI 207.7, sentiment BULLISH.
Processa Pharmaceuticals, Inc. Community Discussion
0Share your Processa Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.